Avoid common mistakes on your manuscript.
A scoping review of the criteria used for major acute kidney events (MAKE) by Maeda and colleagues, published in Intensive Care Medicine highlights the need for a “RE-MAKE” [1]. The composite outcome of death, dialysis, and worsened kidney function, MAKE, was first introduced into the literature 13 years ago [2]. MAKE endpoint utilization in clinical research is growing, with a current PubMed search revealing over 350 investigations in the last 5 years. Maeda et al. show that significant heterogeneity exists when and how its components are applied across studies [1]. Notably, although the constituents of MAKE align with patient-centered principles, they do not differentiate the relative clinical significance of each component. As we now recognize the crucial role of including the perspectives of persons with lived experiences (PWLE) in defining endpoints in acute kidney injury (AKI) trials [3], we propose re-evaluating how we operationalize MAKE with two adaptions.
The use of hierarchical composite endpoints (HCE), based on the concept of a “win ratio” (WR), allows for the assessment of individual events based on clinical relevance and importance to PWLE. We suggest that the WR method prioritizes clinical components of MAKE and evaluates events in pre-specified order of importance, comparing patients in the intervention group with those in the control group [4]. While it is attractive to have one clearly defined composite outcome for AKI trials, it may be that different combinations of hierarchical endpoints may be advantageous which warrants future exploration.
We propose an alternative four-component MAKE employing the WR method, termed RE-MAKE, including in suggested order of importance to PWLE: (1) death, (2) AKI, (3) non-recovery from AKI, including dialysis dependency, and (4) slope of glomerular filtration rate (GFR). Importantly, applicable to preventative studies, severe AKI (stages 2 or 3, including receipt of acute renal replacement therapy) was not included with the original MAKE components. After 13 years of studies since the introduction of MAKE, the evidence has grown, supporting the association of severe AKI with significant morbidity and its inclusion in a composite outcome of kidney health. Strikingly, Maeda et al. revealed 37 definitions of “persistent renal dysfunction” across 122 studies [1]. Growing evidence shows that the GFR slope is a strong surrogate endpoint for kidney disease progression, primarily in the setting of chronic kidney disease. It may be an alternative endpoint to persistent renal dysfunction. We suggest that future investigations validate and explore the use of GFR slope in the setting of acute changes in GFR using methods, such as a two-slope mixed-effects model [5].
The proposed RE-MAKE framework, with its prioritized components, aims to provide a more comprehensive and meaningful measure of AKI endpoints, addressing the evolving understanding of kidney health outcomes. Importantly, there is a crucial need for prospective validation of our proposed RE-MAKE, including establishing an optimal time span for defining renal recovery. Of paramount importance is inclusion of PWLE in all aspects of the design and implementation of studies assessing AKI endpoints. This refined approach promises to improve the precision of clinical research and ensures that the outcomes measured truly reflect patient priorities.
Data availability
A data availability statement is not applicable as no data was used for this correspondence.
References
Maeda A, Inokuchi R, Bellomo R, Doi K (2024) Heterogeneity in the definition of major adverse kidney events: a scoping review. Intensive Care Med. https://doi.org/10.1007/s00134-024-07480-x
Shaw A (2011) Models of preventable disease: contrast-induced nephropathy and cardiac surgery-associated acute kidney injury. Contrib Nephrol 174:156–162. https://doi.org/10.1159/000329387
Manafo E, Petermann L, Mason-Lai P, Vandall-Walker V (2018) Patient engagement in Canada: a scoping review of the “how” and “what” of patient engagement in health research. Health Res Policy Syst 16:5. https://doi.org/10.1186/s12961-018-0282-4
Zampieri FG, Serpa-Neto A, Wald R, Bellomo R, Bagshaw SM, Starrt AKI, Investigators R (2024) Hierarchical endpoints in critical care: a post-hoc exploratory analysis of the standard versus accelerated initiation of renal-replacement therapy in acute kidney injury and the intensity of continuous renal-replacement therapy in critically ill patients trials. J Crit Care 82:154767. https://doi.org/10.1016/j.jcrc.2024.154767
Inker LA, Collier W, Greene T, Miao S, Chaudhari J, Appel GB, Badve SV, Caravaca-Fontan F, Del Vecchio L, Floege J, Goicoechea M, Haaland B, Herrington WG, Imai E, Jafar TH, Lewis JB, Li PKT, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Wetzels JFM, Woodward M, Heerspink HJL, Consortium C-ECT, (2023) A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med 29: 1867-1876. https://doi.org/10.1038/s41591-023-02418-0
Acknowledgements
We have also constructed this correspondence with the invaluable perspective of D'Arcy Duquette, a person with lived experience with acute kidney injury and the Chair of the Health Quality Council of Alberta Patient and Family Advisory Committee. We are profoundly grateful for his contribution.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
SMB has received fees for scientific advisory from Baxter, bioMerieux, BioPorto, Novartis, Sea Star Medical, SphingoTec.; SLG has received grant support from BioPorto Diagnostics, Baxter, NuWellis, ExThera Medical, SeaStar Medical, Roche, Otsuka and consulting fees from BioPorto Diagnostics, Baxter, NuWellis, SeaStar Medical, Talphera, Otsuka, Calcimedica, Fresenius. He has ownership interest in MediBeacon Inc. and receives licensing revenues from RAIDAR Health; the remaining authors declare no potential competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This comment refers to the article available online at https://doi.org/10.1007/s00134-024-07480-x.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Fuhrman, D.Y., Bagshaw, S.M., Goldstein, S.L. et al. Major adverse kidney events as an endpoint in acute kidney injury trials: is it time for a RE-MAKE?. Intensive Care Med (2024). https://doi.org/10.1007/s00134-024-07602-5
Accepted:
Published:
DOI: https://doi.org/10.1007/s00134-024-07602-5